SCHEMBL3185192

SCHEMBL3185192

Cc1ccc(C(=O)COC(=O)C(C)(C)C)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.58
NPC1 O15118 6/20 0.58
MAPT P10636 4/20 0.58
ALDH1A1 P00352 1/20 0.58
KMT2A Q03164 4/20 0.54
SMN1; SMN2 Q16637 3/20 0.51
TP53 P04637 1/20 0.51
HPGD P15428 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
POLB P06746 1/20 0.49
TSHR P16473 1/20 0.49
GSK3B P49841 1/20 0.48
LMNA P02545 2/20 0.48
L3MBTL1 Q9Y468 2/20 0.48
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.45
MAPK1 P28482 1/20 0.44
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pibecarb SCHEMBL2109461 0.84 NPC1 (0.56) RAB9ANPC1MAPTALDH1A1KMT2A
SCHEMBL27722372 0.81 LOXL2 (0.49) RAB9ANPC1MAPTALDH1A1KMT2A
SCHEMBL4549475 0.79 RAB9A (0.64) RAB9ANPC1MAPTALDH1A1KMT2A
SCHEMBL27962547 0.78 MAPT (0.66) RAB9ANPC1MAPTALDH1A1KMT2A
SCHEMBL16785739 0.77 RAB9A (0.49) RAB9ANPC1MAPTALDH1A1KMT2A
SCHEMBL11806422 0.77 NPC1 (0.59) RAB9ANPC1MAPTALDH1A1KMT2A
SCHEMBL25893706 0.76 RAB9A (0.60) RAB9ANPC1MAPTALDH1A1KMT2A
SCHEMBL2064455 0.75 NPC1 (0.58) RAB9ANPC1MAPTALDH1A1KMT2A
SCHEMBL859603 0.74 MAOB (0.49) RAB9ANPC1MAPTALDH1A1HPGD
SCHEMBL11273679 0.74 RAB9A (1.00) RAB9ANPC1MAPTALDH1A1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) 2010-01-21 US disclosed
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) 2010-01-21 US disclosed
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. A CORPORATION OF JAPAN (JP) 2010-01-21 US disclosed
EP-1970375-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. (JP) 2008-09-17 EP disclosed
EP-1970375-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF TORAY INDUSTRIES, INC. (JP) 2008-09-17 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100016319-A1 ARYLMETHYLENE UREA DERIVATIVE AND USE THEREOF UROD, UTS2R, SLC14A1 RAB9A 3416/4885NPC1 3662/4885MAPT 733/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.